Pharmacological Management of Traumatic Brain Injury and Implications for Speech Language Pathology

Abstract

This article provides an overview of the pharmacological management of traumatic brain injury (TBI). A basic introduction to key pharmacokinetic and pharmacodynamic principles is used to guide the reader. The goals of the pharmacological management of TBI are explained starting with mild TBI. The main medications used for each medical condition are described with a primary emphasis of effects that may interfere with the role of speech-language pathology (SLP). Some medications may interfere with cognitive, motor, and neuromuscular functions, and others may cause ototoxicity. A basic overview of the pharmacological management of moderate to severe TBI is included because the SLP practitioner may encounter patients with TBI during the recovery phase. The importance of assessment of swallowing evaluations is discussed because the oral route of administration of medications is preferred once the patient is stable.

Keywords

Pharmacology - pharmacokinetics - pharmacodynamics - traumatic brain injury

• References

• 1 Spruill WJ, Wade WE, DiPiro JT, Blouin RA, Pruemer JM , eds. Concepts in Clinical Pharmacokinetics. 6th ed. Bethesda, MD: American Society of Health-Systems Pharmacists; 2014
• 2 Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2 (7872) 81-84
• 3 Arciniegas DB, Anderson CA, Topkoff J, McAllister TW. Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment. Neuropsychiatr Dis Treat 2005; 1 (4) 311-327
• 4 Glauser T, Ben-Menachem E, Bourgeois B , et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47 (7) 1094-1120
• 5 Glauser T, Ben-Menachem E, Bourgeois B , et al; ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54 (3) 551-563
• 6 Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997; 7 (3) 207-212
• 7 Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants—a review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22 (3) 148-156
• 8 Dietary Supplement Health and Education Act of 1994. Available at: http://ods.od.nih.gov/About/DSHEA_Wording.aspx . Accessed May 21, 2014
• 9 National Institute on Drug Abuse. Prescription Drugs: Abuse and Addiction. DHHS Publication No. 11–4881. Washington, DC: U.S. Government Printing Office; 2011
• 10 Rivera JO, Loya AM, Ceballos R. Use of herbal medicines and implications for conventional drug therapy medical sciences. Altern Integ Med 2013; 2 (6) 1-6
• 11 Guidelines for the Management of Severe Traumatic Brain Injury. J Neurotrauma 2007; 24 (Suppl. 01) 1-106
• 12 Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents-Second Edition. Pediatr Crit Care Med 2012; 13 (Suppl. 01) 1-82
• 13 Ramsay MAE, Savege TM, Simpson BRJ, Goodwin R. Controlled sedation with alphaxalone-alphadolone. BMJ 1974; 2 (5920) 656-659
• 14 Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13 (1) 119-126
• 15 Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53 (2) 483-486
• 16 Shields RK, Martello JL, Potoski BA. Is vancomycin ototoxicity a significant risk?. Antimicrob Agents Chemother 2009; 53 (10) 4572-4573 , author reply 4572–4573
• 17 Ma J, Huang S, Qin S, You C. Progesterone for acute traumatic brain injury. Cochrane Database Syst Rev 2012; 10 (10) CD008409